πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

NEUROCRINE BIOSCIENCES Patents

Full USPTO pharma patent portfolio for NEUROCRINE BIOSCIENCES β€” grant dates, expiration, and drug cross-links.

Patents
111
Expiring ≀24m
8

Quick answer

NEUROCRINE BIOSCIENCES has 111 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 8 expire within 24 months β€” use filters for patent-cliff planning.

Page 2 of 3

  1. US 8481731

    Compounds, pharmaceutical composition and methods relating thereto

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8357697

    Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8293729

    Compounds, pharmaceutical composition and methods relating thereto

    Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8263588

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8084614

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8039627

    Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto

    Expires Mon Oct 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7652035

    CRF receptor antagonists and methods relating thereto

    Expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7462625

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7459458

    Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-Ξ±]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto

    Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7446108

    Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists

    Expires Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7427630

    Condensed N-heterocyclic compounds and their use as CRF receptor antagonists

    Expires Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7419983

    Gonadotropin-releasing hormone receptor antagonists and methods related thereto

    Expires Mon Aug 28 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7378552

    Monoamine re-uptake inhibitors and methods relating thereto

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7329669

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Feb 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7304069

    Hydrate of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5Ξ±]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto

    Expires Mon Nov 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7229995

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jun 07 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7179815

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Feb 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7176211

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Feb 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7081459

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jul 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7071200

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jun 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7056927

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7034118

    Corticotropin-releasing factor2 receptors

    Expires Mon Apr 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  23. US 7015226

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Mar 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  24. US 6958342

    Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-Ξ±]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto

    Expires Mon Oct 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  25. US 6951858

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Sep 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  26. US 6939883

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Sep 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  27. US 6933274

    Methods for treatment of diabetes using a peptide analogues of insulin

    Expires Mon Aug 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  28. US 6921761

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jul 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  29. US 6903106

    Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-Ξ±]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto

    Expires Mon Jun 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  30. US 6872728

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Mar 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  31. US 6750350

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jun 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  32. US 6747034

    CRF receptor antagonists and methods relating thereto

    Expires Mon Jun 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  33. US 6740638

    Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

    Expires Mon May 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  34. US 6740656

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon May 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  35. US 6723841

    Corticotropin-releasing factor2 receptors

    Expires Mon Apr 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  36. US 6723721

    CRF receptor antagonists and methods relating thereto

    Expires Mon Apr 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  37. US 6677340

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jan 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  38. US 6673796

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  39. US 6608197

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Aug 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  40. US 6583143

    CRF receptor antagonists and methods relating thereto

    Expires Mon Jun 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  41. US 6562942

    Methods for treatment of diabetes using peptide analogues of insulin

    Expires Mon May 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  42. US 6544999

    Polymorphs of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-&agr;]- pyrimidin-9-yl}phenyl)acetamide and compositions and methods related thereto

    Expires Mon Apr 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  43. US 6541469

    CRF receptor antagonists and methods relating thereto

    Expires Mon Mar 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  44. US 6537998

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  45. US 6531475

    CRF receptor antagonists and methods relating thereto

    Expires Mon Mar 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  46. US 6514982

    CRF receptor antagonists and methods relating thereto

    Expires Mon Jan 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  47. US 6500839

    CRF receptor antagonists and methods relating thereto

    Expires Mon Dec 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  48. US 6489299

    Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

    Expires Mon Nov 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does NEUROCRINE BIOSCIENCES have?

111 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NEUROCRINE BIOSCIENCES patents expire?

8 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.